Display options
Cite
Hakimi Z, Kelleher C, Aballéa S, et al. Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. J Mark Access Health Policy. 2018;6(1):1438721doi: 10.1080/20016689.2018.1438721.
Hakimi, Z., Kelleher, C., Aballéa, S., Maman, K., Nazir, J., Mankowski, C., & Odeyemi, I. (2018). Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. Journal of market access & health policy, 6(1), 1438721. https://doi.org/10.1080/20016689.2018.1438721
Hakimi, Zalmai, et al. "Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK." Journal of market access & health policy vol. 6,1 (2018): 1438721. doi: https://doi.org/10.1080/20016689.2018.1438721
Hakimi Z, Kelleher C, Aballéa S, Maman K, Nazir J, Mankowski C, Odeyemi I. Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. J Mark Access Health Policy. 2018 Mar 20;6(1):1438721. doi: 10.1080/20016689.2018.1438721. eCollection 2018. PMID: 29686801; PMCID: PMC5907635.
Copy Download .nbib Format: NLM
Share it on

J Mark Access Health Policy. 2018 Mar 20;6(1):1438721. doi: 10.1080/20016689.2018.1438721. eCollection 2018.

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.

Journal of market access & health policy

Zalmai Hakimi, Con Kelleher, Samuel Aballéa, Khaled Maman, Jameel Nazir, Colette Mankowski, Isaac Odeyemi

Affiliations

  1. Medical Affairs Department, Astellas Pharma Europe B.V, Leiden, The Netherlands.
  2. Department of Obstetrics and Gynecology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  3. Health Economics and Outcomes Research Department, Creativ-Ceutical SARL, Paris, France.
  4. Health Economics and Outcomes Research Department, Creativ-Ceutical Ltd, London, UK.
  5. Medical Affairs Department, Astellas Pharma Europe Ltd, Chertsey, UK.

PMID: 29686801 PMCID: PMC5907635 DOI: 10.1080/20016689.2018.1438721

[No abstract available.]

Keywords: Cost utility; Markov; incremental cost-effectiveness ratio; mirabegron; muscarinic agents; quality-adjusted life year

References

  1. Actas Urol Esp. 2011 Feb;35(2):73-9 - PubMed
  2. BJU Int. 2010 Aug;106(4):506-14 - PubMed
  3. BJU Int. 2011 Oct;108(7):1132-8 - PubMed
  4. Health Econ. 2014 Sep 23;:null - PubMed
  5. Urology. 2003 Jan;61(1):37-49 - PubMed
  6. BJU Int. 2008 Jun;101(11):1388-95 - PubMed
  7. Curr Med Res Opin. 2008 Aug;24(8):2173-9 - PubMed
  8. Int J Clin Pract. 2006 Aug;60(8):949-58 - PubMed
  9. Eur Urol. 2005 Sep;48(3):464-70 - PubMed
  10. Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5 - PubMed
  11. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429 - PubMed
  12. Eur Urol. 2013 Feb;63(2):296-305 - PubMed
  13. Value Health. 2015 Sep;18(6):783-90 - PubMed
  14. BJU Int. 2004 Feb;93(3):303-10 - PubMed
  15. Int J Clin Pract. 2011 May;65(5):567-85 - PubMed
  16. Eur Urol. 2017 Sep;72 (3):389-399 - PubMed
  17. Value Health. 2008 Sep-Oct;11(5):956-64 - PubMed
  18. Neurourol Urodyn. 1998;17(6):599-611 - PubMed
  19. J Urol. 2003 Mar;169(3):843-8 - PubMed
  20. Med Care. 1997 Nov;35(11):1095-108 - PubMed
  21. Med Decis Making. 1993 Oct-Dec;13(4):322-38 - PubMed
  22. Int J Clin Pract. 2010 Apr;64(5):584-93 - PubMed
  23. Clin Drug Investig. 2015 Feb;35(2):83-93 - PubMed
  24. Pharmacoeconomics. 2011 Jan;29(1):35-49 - PubMed
  25. J Med Econ. 2013 Oct;16(10 ):1246-54 - PubMed
  26. Eur Urol. 2013 Feb;63(2):283-95 - PubMed
  27. BJU Int. 2012 Dec;110(11):1767-74 - PubMed
  28. Neurourol Urodyn. 2018 Mar;37(3):986-996 - PubMed
  29. BJU Int. 2009 Jan;103(2):202-9 - PubMed
  30. Int Urogynecol J. 2012 Aug;23(8):983-91 - PubMed
  31. Can Urol Assoc J. 2017 Mar-Apr;11(3-4):123-130 - PubMed

Publication Types